Zacks Research Downgrades ADMA Biologics (NASDAQ:ADMA) to Hold

ADMA Biologics (NASDAQ:ADMA) was downgraded by analysts at Zacks Research from a “strong-buy” rating to a “hold” rating in a research report issued to clients and investors on Monday,Zacks.com reports.

Several other equities analysts also recently issued reports on ADMA. Cantor Fitzgerald reaffirmed a “neutral” rating on shares of ADMA Biologics in a report on Thursday, March 26th. Wall Street Zen raised shares of ADMA Biologics from a “hold” rating to a “buy” rating in a research note on Sunday. Canaccord Genuity Group initiated coverage on shares of ADMA Biologics in a research note on Monday, April 20th. They issued a “buy” rating and a $21.00 price target on the stock. Finally, Mizuho decreased their price target on shares of ADMA Biologics from $30.00 to $24.00 and set an “outperform” rating on the stock in a research note on Monday, April 13th. Two investment analysts have rated the stock with a Strong Buy rating, one has given a Buy rating and three have assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $25.67.

ADMA Biologics Stock Performance

NASDAQ ADMA traded down $0.40 during mid-day trading on Monday, reaching $10.51. 245,215 shares of the stock were exchanged, compared to its average volume of 5,002,937. The business’s 50 day moving average is $12.73 and its 200-day moving average is $15.64. ADMA Biologics has a 1 year low of $7.21 and a 1 year high of $24.19. The company has a market capitalization of $2.50 billion, a P/E ratio of 17.50 and a beta of 0.82. The company has a debt-to-equity ratio of 0.16, a quick ratio of 3.74 and a current ratio of 6.71.

ADMA Biologics (NASDAQ:ADMA) last announced its quarterly earnings results on Wednesday, February 25th. The biotechnology company reported $0.20 earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of $0.20. The firm had revenue of $139.16 million for the quarter, compared to the consensus estimate of $139.80 million. ADMA Biologics had a net margin of 28.80% and a return on equity of 37.52%. The firm’s quarterly revenue was up 18.4% compared to the same quarter last year. During the same period in the prior year, the firm posted $0.46 earnings per share. On average, equities research analysts forecast that ADMA Biologics will post 0.93 EPS for the current fiscal year.

Insider Buying and Selling

In related news, COO Kaitlin M. Kestenberg-Messina sold 10,096 shares of ADMA Biologics stock in a transaction that occurred on Monday, March 9th. The shares were sold at an average price of $15.63, for a total value of $157,800.48. Following the completion of the transaction, the chief operating officer owned 466,600 shares in the company, valued at approximately $7,292,958. The trade was a 2.12% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director Steve Elms acquired 7,000 shares of the company’s stock in a transaction that occurred on Thursday, March 5th. The stock was acquired at an average price of $15.67 per share, with a total value of $109,690.00. Following the acquisition, the director directly owned 2,038,730 shares of the company’s stock, valued at approximately $31,946,899.10. This represents a 0.34% increase in their position. The disclosure for this purchase is available in the SEC filing. Insiders own 3.70% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. PFG Investments LLC grew its holdings in ADMA Biologics by 4.1% during the 1st quarter. PFG Investments LLC now owns 222,729 shares of the biotechnology company’s stock worth $2,007,000 after acquiring an additional 8,728 shares in the last quarter. Y Intercept Hong Kong Ltd grew its holdings in ADMA Biologics by 1,508.1% during the 1st quarter. Y Intercept Hong Kong Ltd now owns 1,075,422 shares of the biotechnology company’s stock worth $9,690,000 after acquiring an additional 1,008,548 shares in the last quarter. Peregrine Capital Management LLC grew its holdings in ADMA Biologics by 29.8% during the 1st quarter. Peregrine Capital Management LLC now owns 611,826 shares of the biotechnology company’s stock worth $5,513,000 after acquiring an additional 140,370 shares in the last quarter. Inspire Investing LLC grew its holdings in ADMA Biologics by 119.7% during the 1st quarter. Inspire Investing LLC now owns 56,398 shares of the biotechnology company’s stock worth $508,000 after acquiring an additional 30,722 shares in the last quarter. Finally, Janney Montgomery Scott LLC grew its holdings in ADMA Biologics by 11.2% during the 1st quarter. Janney Montgomery Scott LLC now owns 77,118 shares of the biotechnology company’s stock worth $695,000 after acquiring an additional 7,744 shares in the last quarter. Institutional investors and hedge funds own 75.68% of the company’s stock.

ADMA Biologics Company Profile

ADMA Biologics, Inc is a biopharmaceutical company headquartered in Ramsey, New Jersey, that focuses on the development, manufacturing and commercialization of specialty plasma-derived biologics for the treatment of primary immunodeficiency and infectious diseases. Leveraging an integrated model that spans plasma collection, fractionation, formulation and fill-finish operations, ADMA Biologics aims to address unmet needs in immune-compromised and high-risk patient populations.

The company’s marketed product portfolio includes BIVIGAM, a human immunoglobulin intravenous (IGIV) therapy approved by the U.S.